Market Report -- In Play (ZGEN)
November 2, 2009 2:04 AM ET
ZymoGenetics and Bristol-Myers Squibb present final Ph. 1b results for PEG-Interferon lambda in hepatitis C Co and Bristol-Myers Squibb (
BMY) present final results from a Phase 1b clinical trial of PEG-Interferon lambda administered with ribavirin in relapsed and treatment-naive hepatitis C virus patients. The poster included data on 56 patients in the study. Antiviral activity was observed at all dose levels tested. The results will be presented at the American Association for the Study of the Liver Diseases annual meeting in Boston on November 3. Interim results were previously presented at the European Association for the Study of the Liver annual meeting in April 2009.
Briefing.com is the leading Internet provider of live market analysis for U.S. Stock, U.S. Bond, and world FX market participants.
Read more In Play articles
Back to News Home
- MSN Money
- Search MSN Money
- Message Boards
- Site Status
For today's top Money video click here
E-mail this article
Print-friendly version
Discuss this article